The European Investment Bank (EIB) and Grifols announced the signing of a new loan agreement for EUR 85 million to advance the firm's R+D+i efforts to discover new therapeutic uses for plasma proteins in the treatment of rare and chronic diseases. The agreement, signed in Barcelona September 7, 2018, by EIB Vice-President Emma Navarro and Grifols' co-CEOs Raimon Gr fols Roura and V ctor Gr fols Deu, is backed by the Investment Plan for Europe. The loan will support research initiatives that enhance the health and well-being of patients by providing the financial resources necessary to spur innovation in the medical research field in Spain as well as in the rest of the European Union. The agreement will also bolster bioscientific research in the universities, hospitals and research centers that collaborate with Grifols.